ANIK Anika Therapeutics Inc.

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion

BEDFORD, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company, today announced its WristMotion® Total Wrist Arthroplasty (TWA) System was launched at the American Society for Surgery of the Hand (ASSH) 2021 annual meeting in San Francisco, CA. Previously available to select surgeons and patients during a limited launch beginning on June 30, 2021, the WristMotion TWA System is focused on alleviating pain and restoring function of an arthritic wrist joint. The WristMotion TWA System’s novel design maximizes carpal stability and enables rotational freedom, including the “dart thrower’s” motion.

“We are excited to offer surgeons and patients multiple options to treat wrist arthritis with our WristMotion family of products,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “At Anika, we are committed to meaningful innovation and advancing solutions in areas with unmet needs that allow patients to remain active and engaged in the activities they love. Preserving motion and native anatomy are core pillars of our innovation philosophy, and the WristMotion TWA System is a key strategic addition to our portfolio.”

Designed in collaboration with Dr. Arnold-Peter C. Weiss and Dr. Randall Culp, the design of the WristMotion TWA System leverages over 12 years of data focused on stability and improving wrist implants for patients by incorporating Anika’s proprietary taper post fixation for long-term stability and anatomic design for the preservation of motion.

The WristMotion TWA System is a modular joint preservation system that replaces both the radial and carpal sides of the wrist joint for patients suffering from rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. The system incorporates Anika’s proven fixation technology in the central carpal taper post design, also used in the WristMotion Hemiarthroplasty System, which has been in clinical use since 2015, with over 2,600 cases performed to date1. The WristMotion TWA System also utilizes Anika’s dual curvature design feature in the carpal implant combined with the dorsal flange (or hood) which allows for greater range of extension due to the increased implant surface area2. Preclinical robotic testing has demonstrated that the combination of these features provides improved range of motion and rotational freedom compared to competitive devices, consistent with Anika’s design philosophy of preserving the complex kinematics of the native joints2.

“Historically, patients suffering with advanced wrist pain caused by arthritis or trauma were treated with older versions of total wrist arthroplasty systems or with wrist fusions. Existing total wrist arthroplasty implants on the market today may enable some wrist motion but are at higher risk of carpal loosening. Alternatively, a wrist fusion may severely limit a patient’s ability to move and use their wrist. Neither option restores wrist function, and that’s the core reason the WristMotion TWA System is a significant step forward for surgeons and patients,” said Arnold-Peter C. Weiss, M.D., Chief - Hand, Upper Extremity & Microvascular Surgery, Vice Chairman and Professor of Orthopaedics, Warren Alpert Medical School, Brown University.

The WristMotion TWA System has been available to select customers during a limited market release starting after the first case was performed by Dr. Weiss on June 30th. To-date, the early clinical feedback on instrumentation, surgical technique, and post-operative range of motion has been very positive.

“The WristMotion TWA System’s proprietary central threaded taper post helps ensure secure carpal fixation. This secure carpal fixation, coupled with the ability to adjust the height and tension of the wrist joint on the radial side rather than carpal, strengthens the implant’s stability and also preserves the natural center of rotation,” said William B. Geissler, MD, Alan E. Freeland Chair of Hand Surgery, Professor and Chief Division of Hand and Upper Extremity, University of Mississippi. Dr. Geissler was the first surgeon in Mississippi to implant the WristMotion TWA System. “It is truly the next generation of total wrist arthroplasty,” said Dr. Geissler.

The WristMotion TWA System, along with the WristMotion Hemiarthroplasty System, provide surgeons with multiple treatment options for different stages and severities of wrist arthritis. Both options are available in the United States, and the WristMotion Hemiarthroplasty System was recently launched in Europe.

To learn more about WristMotion, or to learn more about ordering it for a surgery, please visit .

1. As of July 31, 2021. Data on file.

2. Preclinical data on file. Results may not correlate to clinical performance.

About Anika

(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit .

Arthrosurface has joined Anika.

For Investor Inquiries:

Anika Therapeutics, Inc.

Mark Namaroff, 781-457-9287

Executive Director, Investor Relations and Corporate Communications

For Media Inquiries:

Greenough

Christine Williamson, 617-922-1289

Senior Vice President



EN
30/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE

Anika Reports Second Quarter 2025 Financial Results

Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fis...

 PRESS RELEASE

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III St...

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat over 35,000 pati...

 PRESS RELEASE

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, Jul...

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the confere...

 PRESS RELEASE

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...

 PRESS RELEASE

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch